Fresenius Medical Care AG/€FME

06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX

About Fresenius Medical Care AG

Fresenius Medical Care, listed under the ticker FME, is a global provider of dialysis services and products for individuals diagnosed with chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in the healthcare sector. Beyond dialysis, Fresenius Medical Care offers a range of other services, including hospital management and related healthcare services, advancing its position as a comprehensive healthcare provider internationally.

Ticker

€FME
Sector

Primary listing

XETRA

Employees

112,445

FME Metrics

BasicAdvanced
€12B
17.01
€2.44
-
€1.44
3.47%

What the Analysts think about FME

Analyst ratings (Buy, Hold, Sell) for Fresenius Medical Care AG stock.

Bulls say / Bears say

At its Capital Markets Day on June 17, 2025, Fresenius Medical Care announced a €1 billion share buyback, pledged a 30–40% dividend payout, and set long-term goals including a mid-teens operating margin by 2030, underlining its strong commitment to shareholder returns.
In Q2 2025, the company achieved 7% organic revenue growth and a 23% rise in net profit at constant currency, exceeded analysts’ revenue forecasts, reiterated its full-year guidance, and launched the initial phase of its €1 billion buyback.
Fresenius Medical Care beat Q1 2025 estimates with €4.88 billion in revenue compared to the €4.85 billion consensus, and €457 million in adjusted operating income versus the €446 million expected, showing solid performance in a tough environment.
Q2 2025 results showed increased patient outflow and more missed treatments than anticipated after a severe flu season, signaling ongoing volume headwinds despite solid referral trends.
In Q1 2025, U.S. same market treatments were unchanged and total dialysis days dropped due to a spike in flu and cold cases in February, highlighting how vulnerable the company remains to seasonal health challenges in its core market.
Following the June 17, 2025 announcement of a €1 billion share buyback, Fresenius Medical Care’s shares fell about 2%, indicating investors have doubts about the company’s growth outlook.
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2025.

FME Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

FME Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €FME

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs